<Suppliers Price>

Labetuzumab

Names

[ CAS No. ]:
219649-07-7

[ Name ]:
Labetuzumab

Biological Activity

[Description]:

Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy[1].

[Related Catalog]:

Research Areas >> Cancer
Signaling Pathways >> Others >> Others

[Target]

CEA[1].


[In Vivo]

Labetuzumab (0.5 mg/rat; i.v.; single) inhibits tumor growth in vivo[1]. Animal Model: Female nu/nu mice (6 to 8-week-old; inject TT cells)[1]. Dosage: 0.5 mg/rat Administration: Intravenous injection; single (1 day post-tumor cell injection) Result: Significantly delaied growth of tumor, and led to 64%-70% inhibition of tumor size between days 32 and 60.

[References]

[1]. Stein R, et al. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Mol Cancer Ther. 2004 Dec;3(12):1559-64.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds